[go: up one dir, main page]

CY1105963T1 - Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης - Google Patents

Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης

Info

Publication number
CY1105963T1
CY1105963T1 CY20071100114T CY071100114T CY1105963T1 CY 1105963 T1 CY1105963 T1 CY 1105963T1 CY 20071100114 T CY20071100114 T CY 20071100114T CY 071100114 T CY071100114 T CY 071100114T CY 1105963 T1 CY1105963 T1 CY 1105963T1
Authority
CY
Cyprus
Prior art keywords
methods
vaccine compositions
capsomepidian
vaccine
compositions
Prior art date
Application number
CY20071100114T
Other languages
English (en)
Inventor
Lutz Gissmann
Martin Muller
Original Assignee
Loyola University Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loyola University Of Chicago filed Critical Loyola University Of Chicago
Publication of CY1105963T1 publication Critical patent/CY1105963T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Εσωκλείονται συνθέσεις εμβολίου, οι οποίες περιλαμβάνουν ιικά καψομερίδια καθώς επίσης και μεθόδους για την παραγωγή τους. Εσωκλείονται επίσης, θεραπευτικές και προφυλακτικές μέθοδοι χρήσης των συνθέσεων εμβολίου.
CY20071100114T 1997-10-06 2007-01-29 Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης CY1105963T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/944,368 US6228368B1 (en) 1997-10-06 1997-10-06 Papilloma virus capsomere formulations and method of use
PCT/US1998/020965 WO1999018220A1 (en) 1997-10-06 1998-10-06 Papilloma virus capsomere vaccine formulations and methods of use

Publications (1)

Publication Number Publication Date
CY1105963T1 true CY1105963T1 (el) 2011-04-06

Family

ID=25481268

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100114T CY1105963T1 (el) 1997-10-06 2007-01-29 Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης

Country Status (21)

Country Link
US (4) US6228368B1 (el)
EP (2) EP1690941B1 (el)
JP (3) JP4520034B2 (el)
KR (1) KR20010030969A (el)
AT (2) ATE349536T1 (el)
AU (1) AU9684698A (el)
BR (1) BR9814606A (el)
CA (1) CA2305382A1 (el)
CY (1) CY1105963T1 (el)
CZ (1) CZ302351B6 (el)
DE (2) DE69841342D1 (el)
DK (1) DK1021547T3 (el)
ES (2) ES2337492T3 (el)
HU (1) HU225893B1 (el)
IL (3) IL135528A0 (el)
NO (2) NO328128B1 (el)
NZ (1) NZ503830A (el)
PL (1) PL195332B1 (el)
PT (1) PT1021547E (el)
TR (1) TR200001842T2 (el)
WO (1) WO1999018220A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011272A2 (de) * 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) * 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
FI107932B (fi) * 1999-02-16 2001-10-31 Mikael Paronen Polymeerikalvo ja menetelmä sen valmistamiseksi
US6551597B1 (en) * 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
ES2233437T3 (es) * 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.
EP1250593B1 (en) * 1999-12-09 2009-03-25 Medimmune, Inc. IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
DE10059630A1 (de) * 2000-12-01 2002-06-06 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von durch humanen Papillomavirus-Typ 18-hervorgerufenem Tumor
WO2003103570A2 (en) 2001-08-01 2003-12-18 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
CN100424094C (zh) * 2001-08-31 2008-10-08 开普敦大学 药物组合物,制备和分离其的方法,及其在制备预防性治疗损害和癌的药物中的应用
US7041500B2 (en) * 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
AU2003232951B2 (en) † 2002-05-17 2009-07-23 University Of Cape Town Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles.
DK1523329T3 (da) 2002-07-05 2013-10-14 Folia Biotech Inc Viruspartikeladjuvant
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
SE0202896D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method for estimating the risk of carcinoma development
SE0202897D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method and kit for quantitative and qualitative determination of human papillomavirus
US7763259B2 (en) * 2003-01-10 2010-07-27 The Regents Of The University Of Colorado Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
US7172773B2 (en) * 2004-04-26 2007-02-06 Renew Life Inc. Food supplement formulation
WO2006028214A1 (ja) * 2004-09-10 2006-03-16 Asahi Glass Company, Limited 経口投与ワクチン
JP5020825B2 (ja) 2004-12-08 2012-09-05 ジェン−プローブ・インコーポレーテッド 複数型のヒトパピローマウイルスに由来する核酸の検出
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
US9428555B2 (en) * 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
EP2154149B1 (en) * 2007-05-29 2019-07-10 Xiamen University A truncated l1 protein of human papillomavirus 6
US8507811B2 (en) * 2009-02-02 2013-08-13 Apple Inc. Touch sensor panels with reduced static capacitance
EP2377879A1 (en) * 2010-04-14 2011-10-19 Deutsches Krebsforschungszentrum N-terminal HPV E7 fusion proteins
WO2015196112A1 (en) 2014-06-19 2015-12-23 The Regents Of The University Of Colorado, A Body Corporate Human papilloma virus constructs
WO2016026919A1 (en) * 2014-08-20 2016-02-25 Ruprecht-Karls-Universität Heidelberg Vaccines and manufacturing methods for treatment and prevention of disease
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
US11382700B2 (en) 2020-05-08 2022-07-12 Globus Medical Inc. Extended reality headset tool tracking and control
US11510750B2 (en) 2020-05-08 2022-11-29 Globus Medical, Inc. Leveraging two-dimensional digital imaging and communication in medicine imagery in three-dimensional extended reality applications

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267890T3 (es) 1991-07-19 2007-03-16 The University Of Queensland Segmento polinucleotido de genoma hpv16.
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
EP1835029A1 (en) 1992-06-25 2007-09-19 Georgetown University Papillomavirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
PT1618888E (pt) * 1993-03-09 2011-04-08 Univ Rochester Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
DE4435907C2 (de) 1994-10-07 1997-07-24 Lutz Prof Dr Gissmann Papillomavirusähnliche Partikel und deren Anwendung
WO1996011272A2 (de) * 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
JP3413020B2 (ja) * 1996-07-17 2003-06-03 株式会社東芝 半導体装置の製造方法
DE19712541C1 (de) 1997-03-25 1998-11-05 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
EP1000157A1 (en) * 1997-07-03 2000-05-17 University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
JP3559048B2 (ja) 1997-08-26 2004-08-25 日本精工株式会社 転がり軸受の製造方法
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Also Published As

Publication number Publication date
IL190554A0 (en) 2008-11-03
IL135528A0 (en) 2001-05-20
JP2010095530A (ja) 2010-04-30
DK1021547T3 (da) 2007-04-23
ATE449852T1 (de) 2009-12-15
BR9814606A (pt) 2002-01-02
NO20091761L (no) 2000-06-02
ES2280104T3 (es) 2007-09-01
DE69836753D1 (de) 2007-02-08
US20060198853A1 (en) 2006-09-07
AU9684698A (en) 1999-04-27
JP2013147507A (ja) 2013-08-01
CA2305382A1 (en) 1999-04-15
KR20010030969A (ko) 2001-04-16
DE69836753T2 (de) 2007-10-25
EP1690941B1 (en) 2009-11-25
ES2337492T3 (es) 2010-04-26
JP5296665B2 (ja) 2013-09-25
HU225893B1 (en) 2007-12-28
DE69841342D1 (de) 2010-01-07
US6228368B1 (en) 2001-05-08
US20090028894A1 (en) 2009-01-29
NO20001768D0 (no) 2000-04-06
EP1021547B1 (en) 2006-12-27
EP1690941A1 (en) 2006-08-16
US7371391B2 (en) 2008-05-13
IL135528A (en) 2008-06-05
JP4520034B2 (ja) 2010-08-04
PL195332B1 (pl) 2007-09-28
EP1021547A1 (en) 2000-07-26
US7754430B2 (en) 2010-07-13
NO328128B1 (no) 2009-12-14
JP2001519161A (ja) 2001-10-23
US20050031636A1 (en) 2005-02-10
HUP0004360A3 (en) 2003-03-28
PT1021547E (pt) 2007-02-28
ATE349536T1 (de) 2007-01-15
CZ20001244A3 (en) 2001-05-16
PL339735A1 (en) 2001-01-02
NO20001768L (no) 2000-06-02
HUP0004360A2 (en) 2001-03-28
CZ302351B6 (cs) 2011-03-30
NZ503830A (en) 2002-09-27
WO1999018220A1 (en) 1999-04-15
TR200001842T2 (tr) 2000-12-21

Similar Documents

Publication Publication Date Title
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE328068T1 (de) Papillomavirus vakzine
ATE264863T1 (de) 28-epirapaloge
MY129263A (en) Vaccine composition
AU1593001A (en) Recombinant gelatin in vaccines
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
DE69812159D1 (de) Derivate des adamantan
DK1036059T3 (da) Adamantanderivater
SE9704546D0 (sv) Novel compounds
DE69726714T2 (de) 9-oximsilyl erythromycin a derivate
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
NO964238L (no) Halofantrin-fri-base for behandling av malaria og blandinger
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
NO20003146D0 (no) Ketonperoksyd-derivater, deres fremstilling og anvendelse
ES2152315T3 (es) Xamoneline tartrato.
AU6722498A (en) Disubstituted biphenyloxazolines
CY1106306T1 (el) Παραγωγα 5-ιμινο-13-δεοξυ ανθρακυκλινης, οι χρησεις τους και διepγασιες παρασκευης αυτων
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней